Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History CRVS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics CRVS

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Corvus Pharmaceuticals Inc

CRVS
Current price
4.25 USD +0.04 USD (+0.95%)
Last closed 3.96 USD
ISIN US2210151005
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 304 602 688 USD
Yield for 12 month +114.65 %
1Y
3Y
5Y
10Y
15Y
CRVS
21.11.2021 - 28.11.2021

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell atopic dermatitis, asthma, psoriasis, and fibrotic diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California. Address: 901 Gateway Boulevard, South San Francisco, CA, United States, 94080

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

15.20 USD

P/E Ratio

Dividend Yield

Financials CRVS

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures CRVS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

Last Year

-151 000 USD

Current Quarter

Last Quarter

EBITDA -31 133 000 USD
Operating Margin TTM
Price to Earnings
Return On Assets TTM -39.21 %
PEG Ratio
Return On Equity TTM -100.13 %
Wall Street Target Price 15.20 USD
Revenue TTM
Book Value 0.72 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -1.03 USD
Diluted Eps TTM -1.03 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation CRVS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA 0.36
Price Book MRQ 6.22

Technical Indicators CRVS

For 52 Weeks

1.77 USD 10.00 USD
50 Day MA 3.83 USD
Shares Short Prior Month 7 080 956
200 Day MA 5.29 USD
Short Ratio 9.84
Shares Short 7 939 714
Short Percent 12.91 %